Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Drug May Block Crohn’s Inflammation
Uncategorized

Drug May Block Crohn’s Inflammation

By medwebOct 1, 2003
Share
Facebook Twitter Email

October 7, 2003

Drug May Block Crohn’s Inflammation

CHICAGO— An investigational drug under study by Alan L. Buchman, MD, associate professor of medicine at Northwestern’s Feinberg School of Medicine, may block the intense abdominal pain, diarrhea, bleeding, and other symptoms of Crohn’s disease, a condition of unknown cause that affects up to 1 million Americans.

After receiving the experimental drug, called CNI-1493, Lynn Rogers, who has Crohn’s disease, experienced a complete remission of her disabling symptoms for more than eight months.

Rogers, 40, a third-grade teacher in Corpus Christi, Texas, who was one of the first people in the United States to receive the drug, was diagnosed with Crohn’s disease in 1997.

None of the standard treatments for Crohn’s disease Rogers received, including corticosteroids, imfliximab, and medications that suppress the immune system—which normally are used for transplant patients—were effective.

CNI-1493 is a mitogen-activated protein kinase inhibitor, a substance that prevents an enzyme from causing white blood cells to produce chemicals that cause inflammation.

Dr. Buchman is conducting a new study of CNI-1493, but only Crohn’s disease patients who have never received the drug are eligible to participate

Share. Facebook Twitter Email

Related Posts

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Rewriting the Role of a Transcription Factor

Mar 19, 2020

Comments are closed.

Latest News

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.